Literature DB >> 7917538

Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. ISDS II Project Investigators.

A Maguire1, M Porta, N Malats, M Gallén, J L Piñol, E Fernandez.   

Abstract

The time interval between onset of symptoms and the diagnosis of cancer [symptom to diagnosis interval (SDI), or duration of symptoms] is a highly complex variable reflecting patient behaviour, the clinical course, the functioning of the health system and tumour biology. In order to assess possible forms of the risk function of SDI upon cancer survival whilst taking into account the effects of age, sex, tumour site and stage at diagnosis, 1887 symptomatic cases of lung, breast, stomach, colon, rectal, bladder cancer and lymphomas registered in the Tumour Registry of the Hospital del Mar (Barcelona) were analysed by means of survival curves and Cox proportional hazards regression. Subjects (mean age 64 years) were followed for a median length of 15 months after diagnosis (follow-up rate 93.5%). SDI showed a weak relationship with tumour stage at diagnosis and with survival: out of the seven sites studied, only in breast cancer was tumour extension at diagnosis significantly influenced by duration of symptoms, and only lung and rectal cancers showed a detectable form of the risk function of SDI upon survival; neither was linear, and for rectal cancer the relationship was complexly related with tumour stage. Hence, results show that forms of the risk function of duration of symptoms on cancer survival are specific to tumour sites, and that the interval should not be represented as a linear, continuous term. Studies analysing more complex sets of factors, processes and forms of the SDI function are needed.

Entities:  

Mesh:

Year:  1994        PMID: 7917538     DOI: 10.1016/0959-8049(94)90293-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

1.  Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.

Authors:  Miquel Porta; Xavier Fabregat; Núria Malats; Luisa Guarner; Alfredo Carrato; Ana de Miguel; Laura Ruiz; Manuel Jariod; Sergi Costafreda; Susana Coll; Juan Alguacil; Josep M Corominas; Ricard Solà; Antonio Salas; Francisco X Real
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

2.  Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study.

Authors:  Miquel Porta; José Pumarega; Olga Ferrer-Armengou; Tomàs López; Joan Alguacil; Núria Malats; Esteve Fernàndez
Journal:  Eur J Epidemiol       Date:  2007-07-18       Impact factor: 8.082

3.  Prognostic implications of emergency admission and delays in patients with breast cancer.

Authors:  Maximino Redondo; Isabel Rodrigo; Teresa Pereda; Rafael Funez; Mercedes Acebal; Emilio Perea-Milla; Eugenio Jimenez
Journal:  Support Care Cancer       Date:  2008-10-08       Impact factor: 3.603

4.  Decreased survival of patients with lung cancer admitted to a teaching hospital through the emergency department in Barcelona, Spain.

Authors:  M Porta; N Malats; E Morell; G Gomez; M Gallén; F Macià; M Casamitjana; X Fabregat
Journal:  J Epidemiol Community Health       Date:  1998-02       Impact factor: 3.710

5.  Demographic factors associated with knowledge of colorectal cancer symptoms in a UK population-based survey.

Authors:  C Yardley; C Glover; T G Allen-Mersh
Journal:  Ann R Coll Surg Engl       Date:  2000-05       Impact factor: 1.891

6.  Symptom-to-diagnosis interval and survival in cancers of the digestive tract.

Authors:  Esteve Fernandez; Miquel Porta; Núria Malats; Josep Belloc; Manuel Gallén
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

7.  Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer's judgement.

Authors:  M Porta; N Malats; J Belloc; M Gallén; E Fernandez
Journal:  Eur J Epidemiol       Date:  1996-12       Impact factor: 8.082

8.  Can early diagnosis of symptomatic colorectal cancer improve the prognosis?

Authors:  Fernando Gonzalez-Hermoso; Julian Perez-Palma; Joaquin Marchena-Gomez; Nieves Lorenzo-Rocha; Vincente Medina-Arana
Journal:  World J Surg       Date:  2004-06-16       Impact factor: 3.352

9.  Do diagnostic and treatment delays for colorectal cancer increase risk of death?

Authors:  Sandi L Pruitt; Amy Jo Harzke; Nicholas O Davidson; Mario Schootman
Journal:  Cancer Causes Control       Date:  2013-02-28       Impact factor: 2.506

10.  The diagnosis of colorectal cancer in patients with symptoms: finding a needle in a haystack.

Authors:  Robert H Fletcher
Journal:  BMC Med       Date:  2009-04-17       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.